Bristol-Myers Squibb Co BMY on Friday reported upbeat second-quarter results.The report came amid an exciting earnings season. Here are some key analyst takeaways.Barclays On Bristol-Myers SquibbAnalyst Carter Gould downgraded the rating to Underweight, while maintaining the price target at $41.Gould explained the downgrade, stating that the recent rally in Bristol-Myers Squibb’s stock, “despite little movement in underlying post-2025 fundamentals,” appears to be “an over-reaction to the IRA news.”The compa ...